Low calorie meal replacement plan

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Heart Failure With Preserved Ejection Fraction

Drug Information

Target Indication

Heart Failure With Preserved Ejection Fraction

Clinical Trial

Last updated: 8/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ONT.L

Oxford Nanopore Technologies plc

Related Pipeline

Pneumonia

Knee Osteoarthritis

Influenza

Chronic Lung Disease

Severe Acute Malnutrition

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts